Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Psilocybin

Phase 3Small molecule

COMPASS Pathways

Psilocybin is a naturally occurring compound from certain mushrooms that is being studied in clinical trials to help treat depression, anxiety, and PTSD by altering brain activity and potentially helping people process difficult emotions.[1] Psilocybin is currently being investigated across 69 indications[3], with its most advanced program in Phase 3.[1]

Psilocybin is one of 1034 small molecule programs targeting Methamphetamine Dependence. It is currently in Phase 3.

69

Indications

212

Total Trials

116

Active Trials

1,033

Competitors

Pipeline

Status by Indication[3][1]

Indication

Methamphetamine DependenceActive, not recruiting

Nicotine DependenceActive, not recruiting

Neuropathic PainActive, not recruiting

Low Back PainActive, not recruiting

Abnormal Emotional StateActive, not recruiting

Depressive DisorderActive, not recruiting

Psychiatric DisorderActive, not recruiting

Migraine DisorderActive, not recruiting

Cognitive ImpairmentActive, not recruiting

Anorexia NervosaActive, not recruiting

Methamphetamine DependencePhase 1

Active, not recruiting

Nicotine DependencePhase 2

Active, not recruiting

Neuropathic PainPhase 2

Active, not recruiting

Low Back PainPhase 1

Active, not recruiting

Abnormal Emotional StatePhase 3

Active, not recruiting

Depressive DisorderPhase 3

Active, not recruiting

Psychiatric DisorderPhase 2

Active, not recruiting

Migraine DisorderPhase 1

Active, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

Anorexia NervosaPhase 2

Active, not recruiting

Showing 10 of 65 indications

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Psilocybin

COMPASS Pathways

Aldactone

Activella

Angiomax

BBaxter Healthcare Corporation

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Low-Molecular-Weight Heparin

Achromycin V

WWyeth-Lederle Vaccines

Nadroparin

Biological Data

UUniversity Hospital, Bordeaux

Aprotinin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Post-Traumatic Stress Disorder

NCT05554094

Phase 1Recruiting

Psilocybin

NCT06899334

Phase 1Recruiting

Psilocybin

NCT06796361

Phase 1Recruiting

Low Back Pain

NCT06355414

Phase 2Recruiting

Generalized Anxiety Disorder

NCT06969170

Phase 2Active, not recruiting

Alcohol Use Disorder

NCT05421065

Clinical

Trials by Indication[1]

Psilocybin43 trials

Psilocybin and Spiritual Practice

Completed·JJohns Hopkins University·Phase 1·NCT00802282·75 enrolled

Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

Completed·UUniversity of Utah·Phase 1·NCT04522804·12 enrolled

Exploratory Study of Low Dose Psilocybin

Withdrawn·UUniversity of Alabama at Birmingham·Phase 1·NCT05227742

Show 40 more trials

Two Doses of Psilocybin for the Treatment of MDD in Adults With Cancer

Recruiting·SSunstone Medical·Phase 2·NCT05947383·56 enrolled

Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter

Not yet recruiting·NNYU Langone Health·Phase 2·NCT07296328·25 enrolled

The Effects of Psilocybin on Shared Experience in Film Processing

Not yet recruiting·WWestern University, Canada·N/A·NCT06529939·30 enrolled

Persisting Effects of Psilocybin

Completed·JJohns Hopkins University·Phase 1/2·NCT02971605·13 enrolled

A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers

Completed·MMycoMedica Life Sciences PBC·Phase 1·NCT07050368·20 enrolled

Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT03604744·28 enrolled

Consciousness, Psilocybin, and Well-Being

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT05592379·6 enrolled

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Withdrawn·MMassachusetts General Hospital·Phase 2·NCT05381974

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

Completed·JJoshua Woolley·Phase 1·NCT02950467·30 enrolled

The RECAP2 Study: Midazolam and Psilocybin

Recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT06692192·60 enrolled

Mood and Cognitive Effects of Psilocybin in Healthy Participants

Withdrawn·OOptimi Health Corporation·Phase 1·NCT05252598

The ENHANCE Study: taVNS and Psilocybin

Recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT05866471·108 enrolled

Clinical and Mechanistic Effects of Psilocybin in Alcohol Addicted Patients

Completed·UUniversity of Zurich·Phase 2·NCT04141501·37 enrolled

The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density

Completed·SSection for Affective Disorders; Northern Stockholm Psychiatry·Phase 2·NCT04630964·35 enrolled

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Recruiting·JJohns Hopkins University·Phase 1/2·NCT05301608·30 enrolled

Naturalistic Study of Microdosing With Psilocybin

Completed·NNational Council of Scientific and Technical Research, Argentina·N/A·NCT05160220·34 enrolled

Precision Functional Brain Mapping in Psilocybin

Completed·WWashington University School of Medicine·Phase 1·NCT04501653·11 enrolled

Effect of SSRIs on Response to Psilocybin Therapy

Withdrawn·CCybin Therapeutics Inc.·Phase 2·NCT05594667

Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT06899334·24 enrolled

Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT05523401·24 enrolled

Comparing the Effects of Psilocin and Psilocybin in Healthy Adults

Active, not recruiting·UUniversity of California, San Francisco·Phase 1·NCT05317689·20 enrolled

Effects of Repeated Psilocybin Dosing in OCD

Active, not recruiting·YYale University·Phase 1·NCT05370911·30 enrolled

Psychopharmacology of Psilocybin in Cancer Patients

Completed·JJohns Hopkins University·Phase 2·NCT00465595·56 enrolled

Psilocybin-assisted Therapy for Phantom Limb Pain

Completed·UUniversity of California, San Diego·Phase 1·NCT05224336·10 enrolled

Comparative Acute Effects of LSD, Psilocybin and Mescaline

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT04227756·32 enrolled

Psilocybin With Intracranial Neural Sensing

Enrolling by invitation·JJoshua Woolley, MD, PhD·Phase 1·NCT06919640·20 enrolled

Frontline Clinician Psilocybin Study

Completed·UUniversity of Washington·Phase 3·NCT05163496·30 enrolled

Visual Surround Suppression and Perceptual Expectation Under Psilocybin

Terminated·UUniversity of Minnesota·Phase 1·NCT04424225·10 enrolled

Psilocybin-facilitated Treatment for Cocaine Use

Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02037126·40 enrolled

Investigation to Understand and Optimize Psilocybin

Recruiting·CCharles Raison·Phase 2·NCT06512194·141 enrolled

UW Psilocybin Pharmacokinetics Study

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT02163707·12 enrolled

Psilocybin-Assisted Therapy for Intergenerational Trauma

Recruiting·RRachel Yehuda·Phase 2·NCT06899165·100 enrolled

Wellcome Leap Psilocybin for OUD

Recruiting·—·Phase 2·NCT06786325·36 enrolled

PRoMiSS: Psilocybin and the Role of Music in Set and Setting

Enrolling by invitation·JJohns Hopkins University·Phase 1·NCT07180108·100 enrolled

State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma

Recruiting·—·Phase 2·NCT06888128·15 enrolled

Subjective Experience Following Psilocybin

Not yet recruiting·UUniversity of Calgary·Phase 2·NCT06768944·128 enrolled

Psilocybin After Trauma Surgery for Pain

Not yet recruiting·TTrent Emerick·Phase 1·NCT07406828·70 enrolled

Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects

Recruiting·MMedical University of Vienna·Phase 1·NCT07490353·85 enrolled

Bioavailability Study of Psilocybin in Normal Adults

Withdrawn·UUniversity of Wisconsin, Madison·Phase 1·NCT05467761

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness

Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 1·NCT06796361·16 enrolled

Treatment Resistant Depression14 trials

Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression

Not yet recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT07211438·40 enrolled

An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)

Active, not recruiting·SSheppard Pratt Health System·Phase 2·NCT04433858·27 enrolled

Psilocybin for Hospitalized Patients with Treatment-resistant Depression

Recruiting·UUniversity Hospital, Ghent·Phase 2·NCT06378229·100 enrolled

Show 11 more trials

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

Not yet recruiting·VVA Office of Research and Development·Phase 3·NCT07226232·240 enrolled

Psilocybin for Treatment-Resistant Depression

Completed·BBrain and Cognition Discovery Foundation·Phase 2·NCT05029466·30 enrolled

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 3·NCT06303739·23 enrolled

The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression

Completed· COMPASS Pathways logo

COMPASS Pathways·Phase 2·NCT04739865·19 enrolled

Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression

Completed·—·N/A·NCT06650800·10 enrolled

Psilocybin rTMS for Treatment Resistant Depression

Recruiting·UUniversity of Texas at Austin·Phase 2·NCT06132178·100 enrolled

Psilocybin Versus Ketamine in Treatment-Resistant Depression

Unknown status·NNational Institute of Mental Health, Czech Republic·Phase 2·NCT05383313·60 enrolled

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

Completed· COMPASS Pathways logo

COMPASS Pathways·Phase 2·NCT03775200·233 enrolled

Psilocybin for Treatment-Resistant Depression

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06230757·40 enrolled

Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression

Recruiting·—·Phase 2·NCT07183748·20 enrolled

Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)

Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT06512220·12 enrolled

Major Depressive Disorder11 trials

Psilocybin for Major Depressive Disorder

Withdrawn·WWashington University School of Medicine·Phase 2·NCT05675800

Effects of Psilocybin in Major Depressive Disorder

Completed·JJohns Hopkins University·Phase 2·NCT03181529·27 enrolled

Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity Markers

Completed·KKhyber Medical University Peshawar·Phase 2·NCT06746441·60 enrolled

Show 8 more trials

Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT06592833·60 enrolled

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Active, not recruiting· COMPASS Pathways logo

COMPASS Pathways·Phase 2·NCT05733546·102 enrolled

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

Unknown status·MMaryland Oncology Hematology, PA·Phase 2·NCT04593563·30 enrolled

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder

Not yet recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT07405606·30 enrolled

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

Active, not recruiting·JJohns Hopkins University·Phase 2·NCT04620759·90 enrolled

A Study of Psilocybin for Major Depressive Disorder (MDD)

Completed·UUsona Institute·Phase 2·NCT03866174·104 enrolled

Psilocybin for Major Depressive Disorder (MDD)

Active, not recruiting·UUsona Institute·Phase 3·NCT06308653·240 enrolled

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Recruiting·SSharmin Ghaznavi·Phase 3·NCT06247839·20 enrolled

Post-Traumatic Stress Disorder8 trials

Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder

Withdrawn·JJohns Hopkins University·Phase 1·NCT05562973

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Completed· COMPASS Pathways logo

COMPASS Pathways·Phase 2·NCT05312151·22 enrolled

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence

Not yet recruiting·UUniversity of Calgary·Phase 2·NCT06885996·76 enrolled

Show 5 more trials

Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder

Active, not recruiting·OOhio State University·Phase 2·NCT05554094·15 enrolled

Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)

Recruiting·JJohns Hopkins University·Phase 1·NCT06989957·40 enrolled

Evaluation of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans

Unknown status·CCombat Stress·Phase 2·NCT05876481·8 enrolled

Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

Unknown status·HHalucenex Life Sciences Inc.·Phase 2·NCT05243329·20 enrolled

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

Recruiting·SSunstone Medical·Phase 2·NCT06902974·70 enrolled

Alcohol Use Disorder7 trials

Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study

Active, not recruiting·AAnders Fink-Jensen, MD, DMSci·Phase 2·NCT04718792·10 enrolled

Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use Disorder

Active, not recruiting·PPeggy C Nopoulos·Phase 2·NCT05421065·20 enrolled

Psilocybin or Ketamine for Alcohol Use Disorder: An Active Comparator Trial

Recruiting·UUniversity of Iowa·Phase 2·NCT06405607·80 enrolled

Show 4 more trials

Psilocybin-assisted Therapy for Treatment of Alcohol Use Disorder

Completed·AAnders Fink-Jensen, MD, DMSci·Phase 2·NCT05416229·60 enrolled

Psilocybin-assisted Therapy for Alcohol Use Disorder

Not yet recruiting·UUniversity of Sydney·Phase 2·NCT06444243·90 enrolled

Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder

Recruiting·NNYU Langone Health·Phase 2·NCT06349083·200 enrolled

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

Recruiting·CCentre Hospitalier Universitaire de Nīmes·Phase 3·NCT07638553·172 enrolled

77 more indications

Depression6 trials

Low-Income Group Psilocybin Assisted Therapy for Depression

Completed·MMatthew Hicks·N/A·NCT06372197·20 enrolled

PET Synaptogenesis After Psilocybin In DEpression Recovery

Withdrawn·WWashington University School of Medicine·Phase 2·NCT05601648

Psilocybin-assisted CBT for Depression

Completed·UUniversity of California, Los Angeles·Phase 1·NCT05227612·16 enrolled

Show 3 more trials

Psilocybin and Depression

Unknown status·UUniversity of Helsinki·Phase 2·NCT03380442·60 enrolled

RCT of Psilocybin-assisted CBT for Depression

Recruiting·UUniversity of California, Los Angeles·Phase 1/2·NCT07281352·50 enrolled

Does Psilocybin Require Psychedelic Effects to Treat Depression?

Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT05710237·60 enrolled

Opioid Use Disorder6 trials

Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use

Withdrawn·JJohns Hopkins University·Phase 2·NCT05242029

Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Recruiting·JJohns Hopkins University·Phase 2·NCT06067737·90 enrolled

Psilocybin for Opioid Use Disorder (OUD)

Recruiting·NNYU Langone Health·Phase 2·NCT06796062·480 enrolled

Show 3 more trials

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

Withdrawn·JJohns Hopkins University·Phase 2·NCT06005662

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT06810310·24 enrolled

Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)

Recruiting·YYale University·Phase 1·NCT06160284·12 enrolled

Psilocybin-Assisted Psychotherapy5 trials

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

Recruiting·UUniversity of Calgary·Phase 2·NCT05995769·128 enrolled

Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)

Unknown status·CClairvoyant Therapeutics·Phase 2·NCT05646303·128 enrolled

Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

Recruiting·CCentre for Addiction and Mental Health·Phase 1·NCT06299319·10 enrolled

Show 2 more trials

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder

Not yet recruiting·—·Phase 2·NCT07296094·36 enrolled

Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy

Not yet recruiting·KKyle Greenway·Phase 2·NCT07373535·16 enrolled

Anxiety5 trials

Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT05847686·55 enrolled

A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer

Completed·UUniversity of Washington·Phase 1·NCT06644170·15 enrolled

Psilocybin Cancer Anxiety Study

Completed·NNYU Langone Health·Phase 1·NCT00957359·29 enrolled

Show 2 more trials

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

Recruiting·UUniversity of Washington·Phase 2·NCT07336238·18 enrolled

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 1/2·NCT00302744·12 enrolled

Anorexia Nervosa5 trials

Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study

Completed·IImperial College London·Phase 1/2·NCT04505189·21 enrolled

Effects of Psilocybin in Anorexia Nervosa

Completed·JJohns Hopkins University·Phase 1·NCT04052568·22 enrolled

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Completed· COMPASS Pathways logo

COMPASS Pathways·Phase 2·NCT05481736·32 enrolled

Show 2 more trials

Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa

Recruiting·RRegion Skane·Phase 2·NCT07169747·40 enrolled

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Completed·UUniversity of California, San Diego·Phase 2·NCT04661514·16 enrolled

Fibromyalgia3 trials

Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

Completed·KKevin Boehnke·Phase 2·NCT05128162·17 enrolled

Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

Unknown status·IImperial College London··NCT05548075·20 enrolled

The Impact of Psilocybin on Pain in Fibromyalgia Patients

Recruiting·MMaastricht University·N/A·NCT06368492·35 enrolled

Chronic pain3 trials

Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain

Completed·EEmory University·Phase 1·NCT05506982·11 enrolled

Psilocybin-facilitated Treatment for Chronic Pain

Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT05068791·30 enrolled

Psilocybin as a Treatment for Chronic Pain in Smokers

Not yet recruiting·YYale University·Phase 1·NCT07118332·10 enrolled

Alcohol Dependence2 trials

Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence

Completed·UUniversity of New Mexico·Phase 2·NCT01534494·10 enrolled

A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence

Completed·NNYU Langone Health·Phase 2·NCT02061293·95 enrolled

Pilot Study2 trials

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

Completed·—·Phase 2·NCT04950608·15 enrolled

Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

Completed·JJohns Hopkins University·Phase 1·NCT01988311·10 enrolled

Cognitive impairment2 trials

Does Psilocybin Change Synaptic Density in Amnestic Mild Cognitive Impairment

Active, not recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT06041152·10 enrolled

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Recruiting·JJohns Hopkins University·Phase 1·NCT04123314·20 enrolled

Effectiveness2 trials

The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals

Completed·NNYU Langone Health·Phase 1·NCT02421263·12 enrolled

Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion

Completed·JJohns Hopkins University·Phase 1·NCT02243813·24 enrolled

Methamphetamine Use Disorder2 trials

Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT05322954·12 enrolled

Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder

Recruiting·PPortland VA Research Foundation, Inc·Phase 1/2·NCT04982796·30 enrolled

Headache2 trials

Repeat Dosing of Psilocybin in Migraine Headache

Completed·YYale University·Phase 1·NCT04218539·18 enrolled

Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)

Terminated·BBeckley Psytech Limited·Phase 1·NCT04905121·4 enrolled

Bipolar Disorder2 trials

Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06706232·10 enrolled

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

Unknown status·SSheppard Pratt Health System·Phase 2·NCT04433845·15 enrolled

Efficacy2 trials

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Active, not recruiting· COMPASS Pathways logo

COMPASS Pathways·Phase 3·NCT05711940·572 enrolled

Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Active, not recruiting· COMPASS Pathways logo

COMPASS Pathways·Phase 3·NCT05624268·255 enrolled

Obsessive-Compulsive Disorder2 trials

Effects of Psilocybin in Obsessive Compulsive Disorder

Recruiting·JJohns Hopkins University·Phase 1·NCT05546658·30 enrolled

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

Recruiting·FFrancisco A Moreno·Phase 1·NCT07347405·30 enrolled

Low back pain2 trials

Psilocybin in Chronic Low Back Pain and Depression

Recruiting·JJohns Hopkins University·Phase 1·NCT06355414·40 enrolled

Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain

Not yet recruiting·YYale University·Phase 2·NCT07306364·45 enrolled

Neuropathic Pain2 trials

Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN

Recruiting·UUnity Health Toronto·Phase 2·NCT06731335·30 enrolled

Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND)

Recruiting·CCentre for Addiction and Mental Health·Phase 2·NCT06518720·16 enrolled

Tics2 trials

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 in Healthy Participants

Completed·MMycoMedica Life Sciences PBC·Phase 1·NCT06326606·24 enrolled

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 in Healthy Participants

Completed·MMycoMedica Life Sciences PBC·Phase 1·NCT06643637·16 enrolled

Suicidal Ideation1 trial

The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation

Completed·SSheppard Pratt Health System·Phase 2·NCT05220410·20 enrolled

Seizure1 trial

Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures

Completed·—·N/A·NCT06647056·4 enrolled

Recurrence1 trial

Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT06430541·20 enrolled

Bipolar Depression1 trial

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression

Recruiting·UUniversity Health Network, Toronto·Phase 1·NCT06506019·30 enrolled

Concussion1 trial

Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy

Recruiting·UUniversity of Calgary·Phase 1·NCT06615908·40 enrolled

Single Dose1 trial

Investigating the Persisting Effects of a Single Dose of Psilocybin on Structural Plasticity in Healthy Older Adults

Recruiting·UUniversity of California, Berkeley·Phase 1·NCT06367738·40 enrolled

Interaction1 trial

Investigating the Interaction of Psilocybin and Context of Its Administration in Healthy Volunteers

Recruiting·RRobin Carhart-Harris, PhD, MA·Phase 2·NCT06626139·120 enrolled

Cannabis Use Disorder1 trial

Psilocybin-assisted Treatment for Cannabis Use Disorder

Recruiting·JJohns Hopkins University·Phase 1·NCT06660381·12 enrolled

Functional Neurological Disorder1 trial

Psilocybin in Functional Neurological Disorder

Recruiting·KKing's College London·N/A·NCT05723276·24 enrolled

Autism1 trial

Psilocybin for Treatment-Resistant Depression in Autism

Recruiting·CCentre for Addiction and Mental Health·Phase 1·NCT06731621·20 enrolled

Cluster headache1 trial

Prophylactic Effects of Psilocybin on Chronic Cluster Headache

Terminated·GGitte Moos Knudsen·Phase 1/2·NCT04280055·10 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder

Completed·NNew York State Psychiatric Institute·Phase 2·NCT04656301·12 enrolled

Amyotrophic Lateral Sclerosis1 trial

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Recruiting·JJohns Hopkins University·Phase 1·NCT06656702·24 enrolled

Non-Small Cell Lung Cancer1 trial

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

Recruiting·AAlan Davis·Phase 2·NCT07216404·10 enrolled

Social Behavior1 trial

Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy Humans

Completed·UUniversity of Zurich·Phase 1·NCT06081179·122 enrolled

TED1 trial

Psychedelic-assisted Group Program for First Responders

Recruiting·EEmpower Research Inc·Phase 1/2·NCT06471959·32 enrolled

Palliative Care1 trial

Pragmatic Trial of Psilocybin Therapy in Palliative Care

Recruiting·—·Phase 2·NCT05403086·100 enrolled

Mindfulness1 trial

Mindfulness-assisted Psychedelic Therapy

Recruiting·UUniversity of Southern California·Phase 2·NCT06233344·40 enrolled

Intestinal Cancer1 trial

Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers

Active, not recruiting·UUniversity of Nebraska·Phase 1·NCT05220046·24 enrolled

Cancer Pain1 trial

Psilocybin in Cancer Pain Study

Recruiting·—·Phase 2·NCT06001749·15 enrolled

Transdiagnostic1 trial

Open-Label Psilocybin Study in Transdiagnostic Population

Recruiting·YYale University·Phase 1·NCT06442423·50 enrolled

Parkinson's Disease1 trial

Psilocybin Therapy for Depression in Parkinson's Disease

Recruiting·JJoshua Woolley, MD, PhD·Phase 2·NCT06455293·60 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Completed·—·Phase 2·NCT04670081·144 enrolled

Anorexia1 trial

Study of Psilocybin for Anorexia in Young Adults

Recruiting·MMarissa Raymond-Flesch, MD, MPH·Phase 2·NCT06399263·40 enrolled

Lyme disease1 trial

Effects of Psilocybin in Post-Treatment Lyme Disease

Completed·JJohns Hopkins University·Phase 1·NCT05305105·20 enrolled

Major Depression1 trial

Anesthesia-Masked Psilocybin Therapy for Major Depression

Not yet recruiting·SStanford University·Phase 2·NCT07479550·10 enrolled

Generalized Anxiety Disorder1 trial

Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder

Recruiting·QQueen's University·Phase 2·NCT06969170·50 enrolled

Methamphetamine1 trial

Psilocybin for Methamphetamine Addiction

Recruiting·KKevin Murnane·Phase 1·NCT06899594·20 enrolled

Cocaine Use Disorder1 trial

Safety Profile of Psilocybin for Cocaine Use Disorder

Recruiting·UUniversity of California, Los Angeles·Phase 1·NCT06102434·10 enrolled

COVID-191 trial

PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout

Completed·UUniversity of Utah·Phase 1·NCT05557643·24 enrolled

Randomized1 trial

Psilocybin-Assisted Randomized Therapy

Not yet recruiting·EEmory University·Phase 2·NCT07332143·150 enrolled

Cardiac Repolarization1 trial

An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics

Completed·UUsona Institute·Phase 1·NCT05478278·60 enrolled

Neuroimaging1 trial

A Randomized Neuroimaging Trial of Psilocybin in Depression

Recruiting·SSunnybrook Health Sciences Centre·Phase 2·NCT06072898·50 enrolled

Borderline personality disorder1 trial

Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder

Completed·UUniversity of Chicago·Phase 2·NCT05399498·9 enrolled

Melanoma1 trial

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Withdrawn·MMultidisciplinary Association for Psychedelic Studies·Phase 2·NCT00979693

Spinal Cord Injury1 trial

Psilocybin to Treat Depression in Spinal Cord Injury

Not yet recruiting·JJames J. Peters Veterans Affairs Medical Center·Phase 1/2·NCT07251491·30 enrolled

Chronic Pelvic Pain1 trial

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

Not yet recruiting·OOregon Health and Science University·Phase 1·NCT06988319·15 enrolled

Severe Alcohol Use Disorder1 trial

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder

Recruiting·—·Phase 2·NCT06160232·62 enrolled

PrEP1 trial

Digital Intervention for Psychedelic Preparation (DIPP): Comparing Meditation and Music-Based Programs

Recruiting·UUniversity College, London·Phase 1·NCT06815653·40 enrolled

Cognition1 trial

The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function

Not yet recruiting·MManoj Doss·Phase 1/2·NCT07079852·48 enrolled

Irritable Bowel Syndrome1 trial

Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS)

Not yet recruiting·NNYU Langone Health·Phase 1·NCT06760533·10 enrolled

Autism Spectrum Disorder1 trial

Psilocybin in Adults With and Without Autism Spectrum Disorder

Completed·KKing's College London·N/A·NCT05651126·67 enrolled

Adult1 trial

A Study of Psychedelics in Healthy Older Adults With Low Well-being

Not yet recruiting·JJennifer Mitchell·Phase 1·NCT07386730·80 enrolled

Fragile X Syndrome1 trial

An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome

Suspended·NNova Mentis Life Science Corp·Phase 2·NCT05832255·10 enrolled

Alcohol Use Disorder (AUD)1 trial

Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

Recruiting·NNathan Brashares Sackett·Phase 2·NCT06853912·40 enrolled

Healing1 trial

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability

Recruiting·JJohns Hopkins University·Phase 1·NCT07053917·20 enrolled

Biomarkers1 trial

The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.

Not yet recruiting·GGabriella Gobbi·Phase 1·NCT07433452·50 enrolled

OCD1 trial

PsilOCD: A Pharmacological-Challenge Feasibility Study

Completed·IImperial College London·Phase 1·NCT06258031·19 enrolled

Double-blind1 trial

Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.

Completed·YYale University·Phase 1·NCT03356483·31 enrolled

Bipolar II Disorder1 trial

Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder

Not yet recruiting·LLakshmi N Yatham·Phase 3·NCT06943573·90 enrolled

Migraine1 trial

Mechanistic Studies of Psilocybin in Headache Disorders

Recruiting·YYale University·Phase 1·NCT06464367·50 enrolled

Perception Disorders1 trial

Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain

Recruiting·UUniversity of California, Berkeley·Phase 1·NCT05265546·80 enrolled

Psychological Distress1 trial

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial

Recruiting·BBruyère Health Research Institute.·Phase 3·NCT07063862·120 enrolled

Depression, Anxiety1 trial

PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial

Active, not recruiting·OOttawa Hospital Research Institute·Preclinical·NCT04754061·20 enrolled

Loneliness1 trial

The Effects of Psilocybin on Social Connectedness

Not yet recruiting·YYale University·Phase 1·NCT07693153·51 enrolled

Older Adults (65-85 Years)1 trial

A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults

Recruiting·UUniversity of Colorado, Denver·Phase 1·NCT07516405·40 enrolled

Psychological1 trial

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Not yet recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT07360301·120 enrolled

Unspecified3 trials

Neural and Physiological Correlates of Psychedelic Sub-states

Active, not recruiting·RRobin Carhart-Harris, PhD, MA·Phase 1·NCT05698511·12 enrolled

Investigation of Psychedelic Effects in Psychoactive Substances

Recruiting·JJohns Hopkins University·Phase 1·NCT06772753·50 enrolled

Optimizing Microdosing and Meditation

Withdrawn·NNational University of Natural Medicine·N/A·NCT06560658

Sources

References

[1]
ClinicalTrials.gov — 212 trial records for Psilocybin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Psilocybin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Psilocybin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — COMPASS Pathways company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: 5-HT2A Agonist[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: COMPASS Pathways

Related News